Kang Muxing, M.D., Ph.D.

DepartmentGastrointestinal Surgery

Medical School:Zhejiang University School of Medicine, China

Academic Rank:Associate Chief Physician


Appointment

Clinical / Research Interests

Multimodality treatment and translational research on malignant tumor of digestive tract, particularly on gastric cancer and pancreatic cancer.

Professional Highlights

Professional Appointments

Education Experience

Research Summary

The recent research achievements has proved some new potential mechanisms about chemoresistance and paraneoplastic diabetes in pancreatic duct adenocarcinoma. The latest research focuses on the exploration of biomarker and sensibilization mechanism of immunotherapy in gastric cancer.

Publications

Kang, Muxing; Zheng, Wen; Chen, Qing; et al. Thymidylate synthase prompts metastatic progression through the dTMP associated EMT process in pancreatic ductal adenocarcinoma. Cancer Lett. 2018; 419:40-52. 

Kang, Muxing; Zhang Yaoyi; Jin Xiaoli; et al. Concurrent Treatment with Anti-DLL4 Enhances Antitumor and Proapoptotic Efficacy of gamma-Secretase Inhibitor in Gastric Cancer. Translational Oncology. 2018; 11(3): 599-608.

Muxing Kang; Wenjie Qin; Miranbieke Buya; et al. VNN1, a potential biomarker for pancreatic cancer-associated new-onset diabetes, aggravates paraneoplastic islet dysfunction by increasing oxidative stress. Cancer Letters. 2016; 373(2):241-250. 

Kang, Muxing; Jiang, Biao; Xu, Bin; et al. Delta like ligand 4 induces impaired chemo-drug delivery and enhanced chemoresistance in pancreatic cancer. CANCER LETTERS. 2013; 330(1):11-21.

Kang, Muxing ; Don Xin; Lu Wenjie; et al. Vanin-1 as A Biomarker for Pancreatic Cancer Associated New-onset Diabetes Has Been Proven in Clinical and Laboratory Research. Pancreas. 2014; 43(8):1374-1374 (45th Anniversary meeting of American pancreatic association).

Current Program

Experimental study of hENT1/TS targeted diagnosis in the prediction of chemosensitivity on pancreatic cancer (81301889). Funding Source: National Natural Science Foundation of China.

The role of ABCA1 in pancreatic cancer associated new-onset diabetes and its feasibility study as a specific molecular marker for early pancreatic cancer (LY19H160042). Funding Source: National Natural Science Foundation of Zhejiang Province.

Find People

Search by Family Name

Find A Department

Search by Departments